There are fewer women who respond to tumour necrosis factor inhibitors (TNFi) among patients with ankylosing spondylitis (AS), a recent study has shown. Additionally, women show reduced treatment response compared to men.
The addition of the oral Janus kinase inhibitor tofacitinib to csDMARDs* resulted in improvements in patient-reported outcomes (PROs) such as physical function, health-related quality of life (HRQoL), and pain in patients with rheumatoid arthritis (RA), according to a sub-study of the ORAL Sync** trial.
Among patients with rheumatoid arthritis, those who are obese are more likely to have worse disease activity, lower functional ability and poorer health-related quality of life compared with their nonobese counterparts, a study has found.
In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.
The use of subcutaneous golimumab, a fully human anti-TNFα* monoclonal antibody, resulted in significant improvement in clinical responses in children with active polyarticular course of juvenile idiopathic arthritis (polyJIA), according to the GO KIDS** trial.
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
Compared to other tumour necrosis factor–α inhibitors (TNFi), infliximab remains superior in reducing Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at 12 weeks, results of a network meta-analysis (NMA) have shown. However, it was sensitive to inclusion of an open-label trial, and its efficacy faded at 24 weeks.
Interleukin (IL)-18 inhibition using the recombinant human IL-18 binding protein tadekinig alfa demonstrated early signs of efficacy and a favourable safety profile in patients with adult-onset Still’s disease (AOSD), a rare inflammatory disease of unknown aetiology, a phase II study shows.
Treatment with subcutaneous secukinumab leads to significant inhibition of radiographic progression and improvement of clinical signs and symptoms in patients with psoriatic arthritis, according to the results of the FUTURE 5 study.
Women with rheumatoid arthritis (RA) appear to have better functional status prior to menopause, with a recent study reporting that menopause is associated with a worsening progression of functional decline in RA.
Both males and females with rheumatoid arthritis (RA) suffer from significantly higher risks of bone fracture than those without RA, according to a new meta-analysis. Specifically, the risks of hip and vertebral fractures are elevated in RA patients.